



Press Release

MEDTECH RECEIVES MARKETING AUTHORIZATION IN AUSTRALIA FOR ROSA ROBOTIC SURGERY SYSTEM AND SIGNS DISTRIBUTION AGREEMENT FOR AUSTRALIA AND NEW ZEALAND

Montpellier, France, May 18, 2015 – MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical robots, announced that it has received official authorization to market its ROSA™ robot in Australia for minimally invasive surgical procedures on the brain, and also spine surgery.

The Company also announced that it signed a distribution contract for Australia and New Zealand with Surgicom, a company specializing in the distribution and marketing of innovative medical devices, particularly in orthopedics. This agreement significantly reinforces Medtech's geographical coverage in the Asia-Pacific region through Surgicom's various offices and commercial agents in Sydney, Melbourne, Adelaide, Perth and Auckland. The entrance into the Australian and New Zealand markets further supports Medtech's strategy to expand its international sales organization.

"This is an important milestone in the company's development and ongoing expansion of our market opportunity. This authorization to market ROSA™ in Australia and the signing of a distribution agreement with Surgicom is a reflection of our strategy to increase our commercial presence at international level, including the Asia-Pacific region, where we already have strong momentum," commented Bertin Nahum, CEO and Founder of Medtech.

About MEDTECH

Founded in 2002 by Bertin NAHUM and based near Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.

In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.

In 2013 Medtech received the « European Company of the Year Award » in the "robotic neurosurgery" category from Frost & Sullivan.

In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.

In October 2014, MEDTECH won the « Révélation » prize in the Mediterranean Deloitte Technology Fast 50 Awards.

CONTACT MEDTECH

Christophe Sibillin
Chief Financial Officer
Tel : +33 (0)4 67 10 77 40

INVESTORS

Corinne Puissant
Tel : +33 (0)1 53 67 36 77
cpuissant@actus.fr

PRESS

Alexandra Prisa (EU)
Tel. : +33(0)1 53 67 36 90
aprisa@actus.fr

Melanie Sollid-Penton (US)
Tel : +1 646-536-7023
msollid@theruthgroup.com